FEATURED

”We aim to be a leading global research and development company. This is a crucial component in our IPR portfolio and underscores our commitment to an ambitious IPR and market strategy”, says Jean Lycke at Mucocort.

“By embracing AI in healthcare, we are transforming how care is delivered and setting a new standard for patient-centered, personalized, and efficient care,” said Nordic Chief Medical Officer Craig Joseph, MD. “Our partnership with BeeKeeperAI and the integration of RightAI into the EHR allows us to introduce AI models that create real-world impact and drive better patient outcomes.”

Jakes Jordaan, CEO at TriCelX: “With the guidance of our Military Advisory Board, which includes Gen. Lance L. Smith and Brigadier Gen. Mark T. Kimmitt, our team is developing a proprietary biological medical countermeasures cell processing platform — to produce native, non-expanded biologics — to help our warriors facing unique threats such as Acute Radiation Syndrome, Traumatic Brain Injury and battlefield wounds.”

The OrganOx metra® System utilizes normothermic machine perfusion, or NMP, to circulate oxygenated blood, medications, and nutrients to donated organs at normal body temperature and near physiological conditions.

“I reached out to Alveo Technologies in our search for a diagnostics company that is open to rich, disruptive collaboration,” observed Dr. Maggie Linn Bartlett, program director for the Global Virus Network and faculty at the John Hopkins Bloomberg School of Public Health. “Together, Alveo and GVN have created a Partner Development Kit that enables GVN members to independently develop tests on Alveo’s be.well™ platform.